Especially, although the levels of IL-6 appear to be undetectable in p53-null NSCLC H1299 cells (Figs. 1E, F and S1A–C, E), IL-6 pre-treatment also enhanced the tolerance of H1299 cells to SA (Fig. S3C, D and Table S1) or CisPt (Fig. S3E, F and Table S1). This evidence concerns the gene IL6 and non-small cell lung carcinoma.